Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Zanwar, Saurabh; Gertz, Morie A.; Muchtar, Eli; Buadi, Francis K.; Kourelis, Taxiarchis; Gonsalves, Wilson; Go, Ronald S.; Hayman, Suzanne; Kapoor, Prashant; Binder, Moritz; Cook, Joselle; Dingli, David; Leung, Nelson; Lin, Yi; Warsame, Rahma; Fonder, Amie; Hobbs, Miriam; Hwa, Yi Lisa; Kyle, Robert A.; Rajkumar, S. Vincent; Kumar, Shaji; Dispenzieri, Angela

doi:10.1038/s41375-024-02243-5

Leukemia

2024

DOI: 10.1038/s41375-024-02243-5

|View full text |Cite

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Saurabh Zanwar,

Morie A. Gertz,

Eli Muchtar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This scenario was recently studied by the Mayo Clinic group. 9 They observed that trying to restore sensitivity to daratumumab with other medications such as carfilzomib, lenalidomide or pomalidomide does not meet with great success. Conversely, rescue with ASCT in eligible patients and with BCL2-inhibitors in subjects who harbour the translocation (11;14) seems more efficacious.…”

mentioning

confidence: 99%

Response matters in light chain amyloidosis, whatever it takes

Palladini,

Milani

2024

Br J Haematol

View full text Add to dashboard Cite

Access to upfront daratumumab for AL amyloidosis is expanding, but it is not universal. Bomsztyk et al. show that patients who do not receive front‐line daratumumab can be effectively rescued with this agent, indicating that deep haematological response should be pursued tenaciously.Commentary on: Bomsztyk et al. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain (AL) amyloidosis after initial bortezomib‐based regime. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19529.

show abstract

mentioning

confidence: 99%

Response matters in light chain amyloidosis, whatever it takes

Palladini,

Milani

2024

Br J Haematol

View full text Add to dashboard Cite

show abstract

Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis

Bazarbachi,

Bhutani,

Radhakrishnan

et al. 2024

American J Hematol

View full text Add to dashboard Cite

show abstract

Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab

Bellofiore,

Palladini,

Milani

2024

Curr Oncol Rep

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Cited by 6 publications

References 15 publications

Response matters in light chain amyloidosis, whatever it takes

Response matters in light chain amyloidosis, whatever it takes

Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis

Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab

Contact Info

Product

Resources

About